JGC
RAPT

J. Goldman & Co’s RAPT Therapeutics RAPT Stock Holding History

J. Goldman & Co’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,936
Closed -$868K – 448
2022
Q1 		$868K Sell
4,936
-1,446
-23% -$273K 0.04% 263
2021
Q4 		$1.88M Buy
+6,382
New +$1.71M 0.1% 206

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

J. Goldman & Co's RAPT Position: Q2 2022 in Review

J. Goldman & Co sold out of RAPT Therapeutics (RAPT) in Q2 2022, closing a stake of 4,936 shares — an estimated $868K sold.

J. Goldman & Co first reported a position in RAPT in Q4 2021 and held it in 2 quarters. The position peaked at $1.88M in Q4 2021. 84 funds tracked by Wall St. Rank hold RAPT as of Q2 2022.

  • J. Goldman & Co reported no remaining RAPT Therapeutics position as of Q2 2022 after selling out during the quarter.
  • J. Goldman & Co sold 4,936 RAPT Therapeutics shares in Q2 2022, an estimated $868K.
  • J. Goldman & Co first reported a position in RAPT Therapeutics in Q4 2021 and held it in 2 quarters.
  • J. Goldman & Co's RAPT Therapeutics position peaked at $1.88M in Q4 2021.
  • 84 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2022.

Based on J. Goldman & Co's 13F filing for Q2 2022, filed 15 Aug 2022.